Kidney International

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria

By Matthew R. Weir, Sarbani Bhaduri, Keung Lee, David Rodman

Trial in peopleInterventions

The paper

Matthew R. Weir, Sarbani Bhaduri, Keung Lee, David Rodman

University of Maryland, Baltimore; Chrysalis BioTherapeutics (United States)

Kidney International, 23 Sep 2026

doi.org/10.1016/j.kint.2026.08.021 PubMed 42778148

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease